High throughput screening assay for UDP-glucuronosyltransferase 1A1 glucuronidation profiling

Assay and Drug Development Technologies

Volumn 5, Issue 3, 2007, Pages 343-354

  Trubetskoy, O V ^a   Finel, M ^c   Kurkela, M ^c   Fitzgerald, M ^b   Peters, N R ^b   Hoffman, F M ^b   Trubetskoy, V S ^a,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Mirus Bio Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALIPHATIC CARBOXYLIC ACID; BIFLAVONOID; BROMOCRIPTINE MESILATE; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE 1A1; HESPERETIN; HYPOPROTOCETRARIC ACID; ISOGINKGETIN; LEOIDIN; PICROTIN; PICROTOXININ; QUERCETIN; TETRA(3,3',5,5' TETRAIODOTHYROACETIC ACID); UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; ENZYME ASSAY; ENZYME BINDING; ENZYME SUBSTRATE; FLUORESCENCE ANALYSIS; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; MICELLE; PERFORMANCE; PHARMACOPHORE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUORESCENCE; GLUCURONOSYLTRANSFERASE; KINETICS; MICELLES;

EID: 34447519099     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.050     Document Type: Article

References (47)

1. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Maclntyre F, et al.: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997;283:46-58.
2. Parkinson A: An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996;24:48-57.
3. Remmel RP: Review of human UDP-glucuronosyl-transferases and their role in drug-drug interactions. In: Drugs and the Pharmaceutical Sciences, Vol. 116: Drug-Drug Interactions (Rodrigues AD, ed.), pp. 89-112. Marcel Dekker, New York, 2000.
4. Burchell B, Brierley CH, Rance D: Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 1995;57:1819-1831.
5. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, et al.: The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997;7:255-269.
6. Tukey RH, Strassburg CP: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581-616.
7. King CD, Rios GR, Green MD, Tephly TR: UDP-glucuronosyltransferases. Curr Drug Metab 2000;1:143-161.
8. Kiang TK, Ensom MH, Chang TK: UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97-132.
9. Zhou S, Chan E, Li SC, Huang M, Chen X, Li X, et al.: Predicting pharmacokinetic herb-drug interactions. Drug Metab Drug Interact 2004;20:143-158.
10. Tanaka E: Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharmacol Ther 1998;23:403-416.
11. Lee BL, Tauber MG, Sadler B, Goldstein D, Chambers HF: Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther 1996;59:14-21.
12. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al.: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201-1208.
13. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, et al.: Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 2004;32:413-423.
14. Court MH: Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 2005;400:104-116.
15. Kemp CA, Flanagan JU, van Eldik AJ, Marechal JD, Wolf CR, Roberts GC, et al.: Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. J Med Chem 2004;47:5340-5346.
16. de Graaf C, Vermeulen NP, Feenstra KA: Cytochrome p450 in silico: an integrative modeling approach. J Med Chem 2005;48:2725-2755.
17. Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL: Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann N Y Acad Sci 2000;919:26-32.
18. Marks BD, Thompson DV, Goossens TA, Trubetskoy OV: High-throughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic Vivid substrates. J Biomol Screen 2004;9: 439-449.
19. Ritter JK, Crawford JM, Owens IS: Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J Biol Chem 1991;266: 1043-1047.
20. Fang JL, Lazarus P: Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8- dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 2004;13:102-109.
21. Malfatti MA, Ubick EA, Felton JS: The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. Carcinogenesis 2005;26: 2019-2028.
22. Peterson S, Bigler J, Horner NK, Potter JD, Lampe JW: Cruciferae interact with the UGT1A1*28 polymorphism to determine serum bilirubin levels in humans. J Nutr 2005;135:1051-1055.
23. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, et al.: Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 2002;30:1266-1273.
24. Maruo Y, Iwai M, Mori A, Sato H, Takeuchi Y: Polymorphism of UDP-glucuronosyltransferase and drug metabolism. Curr Drug Metab 2005;6:91-99.
25. Trubetskoy OV, Shaw PM: A fluorescent assay amenable to measuring production of beta-D-glucuronides produced from recombinant UDP-glycosyl transferase enzymes. Drug Metab Dispos 1999;27:555-557.
26. Chnari E, Nikitczuk JS, Wang J, Uhrich KE, Moghe PV: Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages. Biomacromolecules 2006; 7:1796-1805.
27. Trubetskoy OV, Finel M, Burke TJ, Trubetskoy VS: Evaluation of synthetic polymeric micelles as a stabilization medium for the handling of membrane proteins in pharmaceutical drug discovery. J Pharm Pharmaceut Sci 2006;9:271-280.
28. Kurkela M, Garcia-Horsman JA, Luukkanen L, Morsky S, Taskinen J, Baumann M, et al.: Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem 2003;278:3536-3544.
29. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4:67-73.
30. Radominska-Pandya A, Ouzzine M, Fournel-Gigleux S, Magdalou J: Structure of UDP-glucuronosyltransferases in membranes. Methods Enzymol 2005;400:116-147.
31. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG: In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33:1729-1739.
32. Watanabe Y, Nakajima M, Ohashi N, Kume T, Yokoi T: Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab Dispos 2003;31:589-595.
33. Cohen LH, Remley MJ, Raunig D, Vaz AD: In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003;31:1005-1015.
34. Boersma MG, van der Woude H, Bogaards J, Boeren S, Vervoort J, Cnubben NH, et al.: Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem Res Toxicol 2002;15: 662-670.
35. Friden M, Vanaja K, Nandi VN: Drug-drug interactions of anti-infective drugs: utility of fluorescence CYP inhibition assays in drug discovery. Drug Metab Drug Interact 2006;21:163-185.
36. Trubetskoy OV, Gibson JR, Marks BD: Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 2005;10:56-66.
37. Di Marco A, D'Antoni M, Attaccalite S, Carotenuto P, Laufer R: Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos 2005;33:812-819.
38. Lin JH, Wong BK: Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr Drug Metab 2002;3:623-646.
39. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI: Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 2004;44:1-25.
40. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al.: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006;24:2237-2244.
41. Nagar S, Blanchard RL: Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 2006;38:393-409.
42. 14C]glucuronic acid. Anal Biochem 1980;109:321-329.
43. Ethell BT, Anderson GD, Beaumont K, Rance DJ, Burchell B: A universal radiochemical high-performance liquid chromatographic assay for the determination of UDP-glucuronosyltransferase activity. Anal Biochem 1998;255: 142-147.
44. Baranczewski P, Kallin A, Andersson A, Hagigi S, Aberg M, Postlind H, et al.: Development of an assay using 4-trifluoromethylumbelliferyl as a marker substrate for assessment of drug-drug interactions to multiple isoforms of UDP-glucuronosyltransferases. Assay Drug Dev Technol 2004;2:345-352.
45. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA: In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 2000;28:560-566.
46. Lett E, Kriszt W, de Sandro V, Ducrotoy G, Richert L: Optimal detergent activation of rat liver microsomal UDP-glucuronosyl transferases toward morphine and 1-naphthol: contribution to induction and latency studies. Biochem Pharmacol 1992;43:1649-1653.
47. Sorich MJ, Smith PA, McKinnon RA, Miners JO: Pharmacophore and quantitative structure activity relationship modeling of UDP- glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 2002;12:635-645.